Glasgow Asthma and Allergy Study

Completed

• Conditions: Asthma; Allergy

• Registration Number: NCT01618318
• Lead Sponsor: National Services for Health Improvement Ltd

Brief Summary

In the past, doctors separated people with asthma into two groups, those with "allergic asthma" (about 2/3rds of people) and those with "non-allergic asthma". These labels are not much used now as the treatments for all people with asthma don't depend on this classification. However, new treatments for asthma may become available and the classification may again become important. It could be useful for clinicians to know how to identify which patients are likely to benefit from particular treatments.

Additionally, some new blood tests are becoming available and some of these might help to categorise the type of asthma people have. What the study hopes to do is to identify patient features which make a diagnosis of "allergic asthma" more likely and to see which new blood tests are most likely to be helpful in confirming this diagnosis.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-06
• Study First Submitted: 2012-06-08
• Study First Submitted QC: 2012-06-12
• Study First Posted: 2012-06-13
• Primary Completion: 2013-10
• Study Completion: 2013-10
• Status Verified: 2013-12
• Last Update Submitted: 2013-12-04
• Last Update Posted: 2013-12-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 105

Inclusion Criteria

• Male and female patients aged 18 years old and over with a diagnosis of asthma and having received at least two prescriptions for any asthma medication in the last 12 months, who have signed an informed consent form prior to initiation of any study-related procedure

Exclusion Criteria

• under 18 years
• current smokers
• unwilling or unable to give informed consent
• a clinical diagnosis of COPD
• a history of anaphylaxis (skin prick test)
• participated in any clinical study in the last 12 months

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serum periostin level	1 day	This is a cross sectional study. Participants will be assessed and tests conducted at a single visit

Secondary Outcome Measures

Name	Time	Method
Blood eosinophils expressing CRTh2	1 day
skin prick test	1 day
Serum total IgE	1 day
Blood CD4 cells that are positive for CRTh2	1 day
Blood eosinophil count	1 day
Blood neutrophil count	1 day
Spirometry	1 day

Trial Locations

Locations (1)

NSHI Ltd; 🇬🇧 Dartford, Kent, United Kingdom